Barry Investment Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,949
| Closed | -$216K | – | 121 |
|
|
2024
Q1 | $216K | Sell |
2,949
-404
| -12% | -$31.1K | 0.07% | 106 |
|
|
2023
Q4 | $272K | Sell |
3,353
-907
| -21% | -$70.6K | 0.09% | 88 |
|
|
2023
Q3 | $319K | Sell |
4,260
-39
| -0.9% | -$3K | 0.11% | 83 |
|
|
2023
Q2 | $331K | Sell |
4,299
-1,185
| -22% | -$94.5K | 0.11% | 87 |
|
|
2023
Q1 | $455K | Sell |
5,484
-98
| -2% | -$8.12K | 0.15% | 77 |
|
|
2022
Q4 | $479K | Sell |
5,582
-776
| -12% | -$61.5K | 0.15% | 75 |
|
|
2022
Q3 | $392K | Sell |
6,358
-920
| -13% | -$58K | 0.13% | 80 |
|
|
2022
Q2 | $450K | Sell |
7,278
-848
| -10% | -$52.5K | 0.14% | 83 |
|
|
2022
Q1 | $483K | Sell |
8,126
-673
| -8% | -$43K | 0.13% | 87 |
|
|
2021
Q4 | $639K | Sell |
8,799
-260
| -3% | -$17.9K | 0.17% | 67 |
|
|
2021
Q3 | $633K | Sell |
9,059
-664
| -7% | -$46.6K | 0.18% | 63 |
|
|
2021
Q2 | $669K | Sell |
9,723
-137
| -1% | -$9.15K | 0.18% | 61 |
|
|
2021
Q1 | $637K | Buy |
9,860
+32
| +0.3% | +$2.06K | 0.18% | 59 |
|
|
2020
Q4 | $573K | Sell |
9,828
-306
| -3% | -$18.5K | 0.17% | 55 |
|
|
2020
Q3 | $640K | Sell |
10,134
-515
| -5% | -$35.7K | 0.22% | 43 |
|
|
2020
Q2 | $819K | Sell |
10,649
-998
| -9% | -$76.5K | 0.29% | 37 |
|
|
2020
Q1 | $871K | Buy |
11,647
+1,029
| +10% | +$71.1K | 0.43% | 32 |
|
|
2019
Q4 | $683K | Buy |
10,618
+800
| +8% | +$52.1K | 0.24% | 39 |
|
|
2019
Q3 | $622K | Sell |
9,818
-481
| -5% | -$31.4K | 0.22% | 38 |
|
|
2019
Q2 | $696K | Buy |
10,299
+77
| +0.8% | +$5.07K | 0.24% | 40 |
|
|
2019
Q1 | $665K | Buy |
10,222
+570
| +6% | +$37.9K | 0.21% | 41 |
|
|
2018
Q4 | $604K | Buy |
9,652
+145
| +2% | +$10.1K | 0.23% | 43 |
|
|
2018
Q3 | $734K | Buy |
9,507
+87
| +0.9% | +$6.57K | 0.25% | 39 |
|
|
2018
Q2 | $667K | Sell |
9,420
-1,532
| -14% | -$108K | 0.26% | 39 |
|
|
2018
Q1 | $826K | Buy |
10,952
+1,350
| +14% | +$107K | 0.31% | 37 |
|
|
2017
Q4 | $688K | Buy |
9,602
+1,952
| +26% | +$148K | 0.26% | 41 |
|
|
2017
Q3 | $620K | Buy |
7,650
+451
| +6% | +$34.5K | 0.23% | 43 |
|
|
2017
Q2 | $510K | Buy |
7,199
+1,507
| +26% | +$100K | 0.19% | 48 |
|
|
2017
Q1 | $387K | Buy |
5,692
+2,218
| +64% | +$156K | 0.14% | 51 |
|
|
2016
Q4 | $249K | Sell |
3,474
-675
| -16% | -$50.2K | 0.09% | 61 |
|
|
2016
Q3 | $328K | Buy |
4,149
+835
| +25% | +$67.8K | 0.11% | 55 |
|
|
2016
Q2 | $276K | Buy |
3,314
+224
| +7% | +$19.9K | 0.11% | 57 |
|
|
2016
Q1 | $284K | Buy |
+3,090
| New | +$279K | 0.09% | 65 |
|
Other funds holding GILD
Barry Investment Advisors's GILD Position: Q2 2024 in Review
Barry Investment Advisors sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 2,949 shares — an estimated $216K sold.
Barry Investment Advisors first reported a position in GILD in Q1 2016 and held it in 33 quarters. The position peaked at $871K in Q1 2020. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Barry Investment Advisors reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Barry Investment Advisors sold 2,949 Gilead Sciences shares in Q2 2024, an estimated $216K.
- Barry Investment Advisors first reported a position in Gilead Sciences in Q1 2016 and held it in 33 quarters.
- Barry Investment Advisors's Gilead Sciences position peaked at $871K in Q1 2020.
- 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Barry Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.